Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare ...

BALA CYNWYD, Pa., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare ...

Larimar Therapeutics Inc (LRMR) stock saw a modest uptick, ending the day at $7.14 which represents a slight increase of $0.29 or 4.23% from the prior close of $6.85. The stock opened at $7.08 and ...

Fintel reports that on September 12, 2024, Jones Trading initiated coverage of Larimar Therapeutics (NasdaqGM:LRMR) with a ...

BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) is set to present pivotal data from its nomlabofusp Phase 1 and ...

(MENAFN- GlobeNewsWire - Nasdaq) BALA CYNWYD, Pa., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage ...

Larimar Therapeutics (LRMR) has received a new Buy rating, initiated by Robert W. Baird analyst, Joel Beatty. Joel Beatty has given his Buy ...

Fintel reports that on September 12, 2024, Jones Trading initiated coverage of Larimar Therapeutics (NasdaqGM:LRMR) with a Buy recommendation. As of August 26, 2024, the average one-year price ...

BALA CYNWYD, Pa., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare ...

On Wednesday, Larimar Therapeutics (NASDAQ:LRMR) received a Buy rating from Jones Trading, with a set price target of $14.00. The firm expressed optimism about Larimar's primary product ...